每经AI快讯，7月29日，美股医疗保健板块集体下挫。诺和诺德跌超19%，默沙东跌超8%，礼来跌超 5%。 ...

21:30 美股开盘丨三大指数高开诺和诺德跌超21% | 标普500期货小型 | 6433.00d 10.25 00.16% | | | --- | --- | --- | | 纳斯达克100期货小型 23575.50d | 84.25 0.36% | | | 纳斯达克100期货微型│ 23575.00d│ | 83.75 0.36% | | | 45032d 道琼斯期货小型 | 20 - | 0.04% | 21:15 欧洲主要股指齐涨 德国DAX指数涨1.27%，法国CAC40指数涨1.34%，英国富时100指数涨0.72%。 | 名称 现价 | | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 英国富时100 | 9147.10 | 65.66 | 0.72% | | 法国CAC40 | 7905.45 | 104.57 | 1.34% | | 德国DAX | 24274.27 | 303.91 | 1.27% | | 意大利富时Ml 41342.34 | | 610.00 | 1.50% | | 欧元区STOXX 5401.09d | | 63.51 | 1.19% | ...

诺和诺德跌超21%，公司下调2025年展望；波音涨逾1%，公司第二季度营收同比增长35%；联合健康集 团跌逾5%，下调医疗保险目标范围。 （持续更新中……） 21:30 美股开盘丨三大指数高开 诺和诺德跌超21% | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 英国富时100 | 9147.10 | 65.66 | 0.72% | | 法国CAC40 | 7905.45 | 104.57 | 1.34% | | 德国DAX | 24274.27 | 303.91 | 1.27% | | 意大利富时Ml 41342.34 | | 610.00 | 1.50% | | 欧元区STOXX 5401.09d | | 63.51 | 1.19% | 道指涨0.08%，纳指涨0.52%，标普500指数涨0.26%。诺和诺德跌超21%，公司下调2025年展望；波音 涨逾1%，公司第二季度营收同比增长35%；联合健康集团跌逾5%，下调医疗保险目标范围。 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 道琼斯工业指数 | ...

美股开盘，道指接近平开，标普500指数涨0.24%、纳指涨0.5%。诺和诺德(NVO.N)跌21%，公司下调 2025年销售增长及利润预期。默沙东(MRK.N)跌5.4%，公司宣布裁员计划；波音(BA.N)涨1.5%，二季 度业绩超预期。纳斯达克中国金龙指数涨0.7%。 ...

1. "美联储传声筒"：美联储本周还没准备好降息。 2. 阿斯利康(AZN.O)Q2营收同比增12%至144.6亿美元超预期。 3. 诺和诺德美股盘前(NVO.N)一度跌超26%，公司下调2025年展望。 4. 波音(BA.N)2025年Q2营收227.5亿美元，市场预期218.44亿美元。 6. 联合健康(UNH.N)将医疗保险目标范围从3%-5%下调至2%-4%。 7. 巴克莱(BCS.N)上半年利润增长23%，宣布13亿美元股票回购计划。 8. 惠而浦(WHR.N)盘前跌超17%，Q2业绩不及预期，下调全年盈利指引。 9. 飞利浦(PHG.N)盘前涨近10%，因关税冲击弱于预期，上调全年盈利预期。 10. Stellantis(STLA.N)恢复业绩指引，预警下半年将面临12亿欧元关税冲击。 12. 截至3月31日，伯克希尔哈撒韦(BRK.A.N、BRK.B.N)持有约1329万股威瑞信股票。 （文章来源：金十数据） 5. 默沙东(MRK.N)2025年Q2营收158.1亿美元，同比减少2%。 11. 野村控股(NMR.N)美股盘前涨超4%，第一季度净利润同比增长51.7%。 ...

默沙东(MRK.N)将本财年销售额预期缩小至643亿至653亿美元，而之前的预期为641亿至656亿美元。 ...

默沙东(MRK.N)将裁员，通过重组节省30亿美元。 ...

Group 1 - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 1.56%, with notable gains from stocks such as MicroPort Medical (00853) up 16.53% and WuXi AppTec (02268) [3] - The Hang Seng Healthcare ETF (513060) rose by 1.24%, with a recent price of 0.65 yuan, and has accumulated a 4.21% increase over the past week [3] - The National Healthcare Security Administration reported that since the 14th Five-Year Plan, 402 types of drugs have been added to the national medical insurance drug list, which now includes a total of 3,159 drugs [3] Group 2 - CD3 T cell engagers (TCE) are gaining significant attention in the field of autoimmune diseases, with advantages such as precise targeting and reduced toxicity [4] - The Hang Seng Healthcare ETF has a current scale of 79.17 billion yuan, ranking in the top third among comparable funds [4] - The ETF has shown a net value increase of 30.43% over the past two years, with a maximum monthly return of 28.34% since its inception [4] Group 3 - The Hang Seng Healthcare ETF has a Sharpe ratio of 2.22 for the past year, indicating strong risk-adjusted returns [5] - The ETF's management fee is 0.50%, and the tracking error over the past year is 0.060%, the highest precision among comparable funds [5] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 31.13, indicating it is at a historical low compared to the past three years [5] Group 4 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 60.62% of the index, including companies like BeiGene (06160) and Innovent Biologics (01801) [6] - The ETF is closely tracking the Hang Seng Healthcare Index, which serves as a market reference for healthcare-related securities listed in Hong Kong [5][6]

Core Viewpoint - The acquisition of Lixin Pharmaceutical by China Biologic Pharmaceutical marks a significant milestone in the domestic innovative drug sector, with a transaction value of up to $9.51 billion (approximately 68.22 billion RMB), creating the largest merger record in this field for 2025 [2][25]. Group 1: Acquisition Details - China Biologic Pharmaceutical announced the acquisition of 95.09% of Lixin Pharmaceutical's shares for a maximum consideration of $9.51 billion, with a net payment of approximately $5.01 billion after accounting for Lixin's cash reserves of about $4.5 billion [2][9]. - The acquisition was completed in about two months, highlighting the strong collaboration between the two companies, particularly in the development of the LM-108 project [8][18]. - Lixin Pharmaceutical was founded in 2019 by Dr. Qin Ying and has attracted significant investment from various venture capital firms, providing a valuable exit opportunity for its investors [4][20]. Group 2: Leadership and Strategic Vision - The acquisition was led by 90s-born chairperson Xie Qirun, a member of the Charoen Pokphand Group, who has been instrumental in the strategic planning and international operations of China Biologic Pharmaceutical [12][13]. - Xie expressed that the core value of the acquisition lies in the integration of innovative drug development capabilities with industrialization, aiming for a synergistic effect that exceeds the sum of its parts [18]. Group 3: Market Context and Future Outlook - The acquisition reflects a broader trend in the pharmaceutical industry, where domestic companies are increasingly engaging in mergers and acquisitions, moving away from reliance on foreign giants [34]. - The innovative drug sector has seen a resurgence, with several companies experiencing significant stock price increases and successful IPOs, indicating a favorable market environment for biotech investments [28][33]. - The successful merger of China Biologic Pharmaceutical and Lixin Pharmaceutical signals a potential turning point for domestic biotech firms, suggesting that the industry may be entering a new growth phase [35].

Core Viewpoint - The article highlights the significant transformation in the perception of China's biotech innovation capabilities by multinational pharmaceutical companies, particularly Roche, which has increased its investment and collaboration in the Chinese market [1][2]. Group 1: Investment and R&D Expansion - Roche has established a strong presence in China through its innovation center and accelerator, investing nearly 300 million RMB and facilitating numerous early-stage research collaborations [5][12]. - Shanghai has become a hub for multinational pharmaceutical companies, with six of the top ten global firms setting up R&D centers or incubators in the city, reflecting a shift towards open innovation and collaboration with local firms [3][6]. Group 2: Strategic Collaborations and Acquisitions - Recent high-profile licensing deals, such as the one between Shanghai-based Innovent Biologics and Pfizer, highlight the growing trend of multinational companies acquiring innovative drug pipelines from local firms, with upfront payments reaching record amounts [12][13]. - The article notes that the number of licensing transactions in China has surged, with the country accounting for 42% of global licensing deals with upfront payments exceeding $50 million in early 2025 [14][15]. Group 3: Innovation Ecosystem in Shanghai - Shanghai's biopharmaceutical industry has evolved significantly, with industrial output exceeding 200 billion RMB, supported by a robust ecosystem of research institutions, hospitals, and government policies promoting innovation [17][18]. - The city has established a comprehensive innovation ecosystem, enhancing the entire industry chain from R&D to clinical applications, which has attracted significant foreign investment and collaboration [19][20].